These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 12053490)

  • 21. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
    Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
    Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circadian rhythmicity and cross correlation of plasma gastrin, cortisol and somatostatin levels in ulcerative colitis patients and healthy subjects.
    Payer J; Huorka M; Duris I; Mikulecký M; Kratochvíl'ová H; Ondrejka P
    Hepatogastroenterology; 1993 Jun; 40(3):272-5. PubMed ID: 8100796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
    Raderer M; Hamilton G; Kurtaran A; Valencak J; Haberl I; Hoffmann O; Kornek GV; Vorbeck F; Hejna MH; Virgolini I; Scheithauer W
    Br J Cancer; 1999 Feb; 79(3-4):535-7. PubMed ID: 10027326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.
    Raderer M; Hejna MH; Kurtaran A; Kornek GV; Valencak JB; Oberhuber G; Vorbeck F; Virgolini I; Scheithauer W
    Am J Gastroenterol; 1999 Jan; 94(1):278-9. PubMed ID: 9934776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabergoline plus lanreotide for ectopic Cushing's syndrome.
    Pivonello R; Ferone D; Lamberts SW; Colao A
    N Engl J Med; 2005 Jun; 352(23):2457-8. PubMed ID: 15944436
    [No Abstract]   [Full Text] [Related]  

  • 27. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
    Skinazi F; Zins M; Menu Y; Bernades P; Ruszniewski P
    Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):673-8. PubMed ID: 8853257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
    Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
    Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of delayed-release lanreotide in the medical therapy of acromegaly].
    Papi G; Magnoni I; Pesenti M; Gola M; Tavernari V; Velardo A
    Minerva Endocrinol; 1998 Jun; 23(2):57-63. PubMed ID: 9844356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting formulations of somatostatin analogues.
    Anthony LB
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
    Modlin IM; Pavel M; Kidd M; Gustafsson BI
    Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.
    Maulard C; Richaud P; Droz JP; Jessueld D; Dufour-Esquerré F; Housset M
    Cancer Chemother Pharmacol; 1995; 36(3):259-62. PubMed ID: 7540120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].
    Zieliński G; Podgórski JK; Koziarski A; Siwik J; Zgliczyński W; Wieliczko W
    Neurol Neurochir Pol; 2001; 35(3):423-37. PubMed ID: 11732266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Occurrence of carcinoid syndrome in patients with carcinoid tumors].
    Kinová S; Kovácová E; Bulas J; Murín J; Belovicová M; Jurkovicová I; Duris I
    Vnitr Lek; 2004 Feb; 50(2):126-33. PubMed ID: 15077587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency.
    Barbanoj M; Antonijoan R; Morte A; Grinyó JM; Solà R; Vallès J; Peraire C; Cordero JA; Muñoz A; Jané F; Obach R
    Clin Pharmacol Ther; 1999 Nov; 66(5):485-91. PubMed ID: 10579475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of lanreotide for the treatment of gastrointestinal fistulae.
    Clive K; Hardin M; White C; Larson C; Oh J; Cohn S
    Ann Surg; 2011 Jan; 253(1):211; author reply 211-2. PubMed ID: 21135689
    [No Abstract]   [Full Text] [Related]  

  • 40. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.